checkAd

     109  0 Kommentare AlzeCure Publishes its Year-end Report for January - December 2023

    STOCKHOLM, SWEDEN / ACCESSWIRE / February 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January - December 2023 is now available on the company's …

    STOCKHOLM, SWEDEN / ACCESSWIRE / February 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January - December 2023 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/

    "The fourth quarter of 2023 continued to be positive and eventful for AlzeCure Pharma. During the period, we presented new preclinical data which show that our clinical drug candidate NeuroRestore ACD856 potentially has neuroprotective and disease-modifying effects in Alzheimer's and other neurodegenerative diseases. We also received new patents for ACD856 and published new data for NeuroRestore and Alzstatin validating the target mechanisms and stimulating interest in the two Alzheimer's programs. In addition, we presented phase II clinical results for ACD440 for the treatment of peripheral neuropathic pain. It is both motivating and gratifying that we are keeping up the pace as we continue to deliver new data that strengthen our position. Furthermore, we have now also selected a drug candidate in our TrkA-NAM project, ACD137."

    Martin Jönsson, CEO

    Financial information for October - December, 2023
    Figures in parentheses refer to the corresponding period of the previous year.

    • Net sales during the period totaled SEK 0 thousand (0).
    • Earnings for the period totaled SEK -9,756 thousand (-10,948).
    • Earnings per share, basic, totaled SEK -0.16 (-0.22).
    • Cash flow from operating activities totaled SEK -8,361 thousand (-51,194).
    • Total assets at the end of the period amounted to SEK 32,001 thousand (70,836).
    • Cash and cash equivalents at the end of the period totaled SEK 29,100 thousand (25,577).

    Financial information for January - December, 2023
    Figures in parentheses refer to the corresponding period of the previous year.

    • Net sales during the period totaled SEK 0 thousand (0).
    • Earnings for the period totaled SEK -37,167 thousand (-56,239).
    • Earnings per share, basic, totaled SEK -0.60 (-1.18).
    • Cash flow from operating activities totaled SEK 3,057 thousand (-99,911).
    • Total assets at the end of the period amounted to SEK 32,001 thousand (70,836).
    • Cash and cash equivalents at the end of the period totaled SEK 29,100 thousand (25,577).

    Significant events during the period October - December, 2023

    Seite 1 von 3



    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    AlzeCure Publishes its Year-end Report for January - December 2023 STOCKHOLM, SWEDEN / ACCESSWIRE / February 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January - December 2023 is now available on the company's …